| scholarly article | Q13442814 |
| P50 | author | Noemi D'Atanasio | Q89778126 |
| P2093 | author name string | Serena Tongiani | |
| Francesco Paolo Di Giorgio | |||
| Federica Prati | |||
| Rosella Ombrato | |||
| Claudio Milanese | |||
| Carla Vignaroli | |||
| Gabriele Magarò | |||
| Giorgina Mangano | |||
| Marco Vitiello | |||
| Laura Di Sante | |||
| Alessandra Capezzone de Joannon | |||
| Cristina Bartella | |||
| P2860 | cites work | DNA topoisomerases: structure, function, and mechanism | Q22065417 |
| Cellular roles of dna topoisomerases: a molecular perspective | Q22121990 | ||
| The life and times of the Enterococcus | Q24616875 | ||
| Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challenge | Q26796265 | ||
| Type IIA topoisomerase inhibition by a new class of antibacterial agents | Q27663884 | ||
| Prevalence of the oqxAB gene complex in Klebsiella pneumoniae and Escherichia coli clinical isolates. | Q54318001 | ||
| Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem. | Q54656558 | ||
| National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, issued August 2001 | Q56898125 | ||
| Contribution of OqxAB efflux pumps to quinolone resistance in extended-spectrum- -lactamase-producing Klebsiella pneumoniae | Q59617399 | ||
| PCR amplification of streptococcal DNA using crude cell lysates | Q60120294 | ||
| DNA Topoisomerases | Q64390034 | ||
| Differential sensitivities of recombinant human topoisomerase IIalpha and beta to various classes of topoisomerase II-interacting agents | Q77379571 | ||
| Novobiocin jaundice | Q78709601 | ||
| Addressing the emergence and impact of multidrug-resistant gram-negative organisms: a critical focus for the next decade | Q87410442 | ||
| Virtual Screening Approach and Investigation of Structure-Activity Relationships To Discover Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Positive and Gram-Negative Pathogens | Q91649556 | ||
| Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases | Q27685406 | ||
| Escherichia coli Harboring mcr-1 and bla CTX-M on a Novel IncF Plasmid: First Report of mcr-1 in the United States | Q28005483 | ||
| Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance | Q29617469 | ||
| Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve | Q33181940 | ||
| Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence | Q33558978 | ||
| In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations | Q33561341 | ||
| TolC, an Escherichia coli outer membrane protein required for hemolysin secretion. | Q33644353 | ||
| Mode of action of fluoroquinolones | Q33770059 | ||
| Challenges of antibacterial discovery | Q33793074 | ||
| Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 gram-positive and -negative bacteria | Q33978553 | ||
| The fluoroquinolone antibacterials: past, present and future perspectives | Q34143393 | ||
| Mechanisms of action of antimicrobials: focus on fluoroquinolones | Q34183520 | ||
| Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli | Q34297971 | ||
| In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class | Q34510396 | ||
| Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase | Q35042255 | ||
| Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder | Q35546189 | ||
| In Vitro and In Vivo Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA Gyrase | Q37119995 | ||
| Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options | Q37150308 | ||
| NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy | Q37713025 | ||
| Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success | Q38212925 | ||
| In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens | Q38741791 | ||
| Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria. | Q38949284 | ||
| Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus. | Q39471404 | ||
| Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. | Q39784317 | ||
| The acrAB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump | Q39847810 | ||
| Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus | Q40286293 | ||
| DNA gyrase action involves the introduction of transient double-strand breaks into DNA | Q40602513 | ||
| Cytotoxicity and DNA Topoisomerase Inhibitory Activity of Benz[f]indole-4,9-dione Analogs | Q40629892 | ||
| Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus | Q40833065 | ||
| Trends in bacterial resistance to fluoroquinolones | Q41311555 | ||
| In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria | Q41668866 | ||
| In vitro pharmacodynamics of AZD5206 against Staphylococcus aureus | Q41875874 | ||
| Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases | Q41925162 | ||
| Early identification of hERG liability in drug discovery programs by automated patch clamp | Q41989274 | ||
| A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry | Q43513018 | ||
| Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile | Q46759921 | ||
| The mechanism of inhibition of topoisomerase IV by quinolone antibacterials | Q46829877 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P304 | page(s) | e0228509 | |
| P577 | publication date | 2020-02-19 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors | |
| P478 | volume | 15 |
Search more.